PE20240825A1 - ANTI-C5 ANTIBODIES AND METHODS OF USE - Google Patents
ANTI-C5 ANTIBODIES AND METHODS OF USEInfo
- Publication number
- PE20240825A1 PE20240825A1 PE2023002969A PE2023002969A PE20240825A1 PE 20240825 A1 PE20240825 A1 PE 20240825A1 PE 2023002969 A PE2023002969 A PE 2023002969A PE 2023002969 A PE2023002969 A PE 2023002969A PE 20240825 A1 PE20240825 A1 PE 20240825A1
- Authority
- PE
- Peru
- Prior art keywords
- antibodies
- seq
- beta chain
- epitope
- domain
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000008228 bacteriostatic water for injection Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 101100177112 Caenorhabditis elegans his-70 gene Proteins 0.000 abstract 1
- 101100069975 Caenorhabditis elegans his-72 gene Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invencion refiere a anticuerpos anti-C5, los cuales se unen a un epitopo dentro de la cadena beta (SEQ ID NO: 40) de C5 con una mayor afinidad a pH neutro que a pH acido. Dichos anticuerpos se unen a un epitopo dentro del dominio MG1-MG2 de la cadena beta (SEQ ID NO: 40) de C5, la cual comprende al menos un aminoacido seleccionado de Glu48, Asp51, His70, His72, Lys109 e His110. Tambien, se refiere a metodos para producir los anticuerpos que comprenden el cultivo de una celula hospedera con un acido nucleico que los codifica, y la inmunizacion de un animal contra un polipeptido que comprende el dominio MG1-MG2 de la cadena beta (SEQ ID NO: 40) de C5. Ademas, refiere a un articulo de manufactura que contiene una formulacion farmaceutica a base de un anticuerpo anti-C5 y un tampon farmaceuticamente aceptable seleccionado de agua bacteriostatica para inyeccion (BWFI) tamponada con fosfato solucion salina, solucion de Ringer y solucion de dextrosa, para su uso como medicamento.The present invention relates to anti-C5 antibodies, which bind to an epitope within the beta chain (SEQ ID NO: 40) of C5 with a greater affinity at neutral pH than at acidic pH. Said antibodies bind to an epitope within the MG1-MG2 domain of the beta chain (SEQ ID NO: 40) of C5, which comprises at least one amino acid selected from Glu48, Asp51, His70, His72, Lys109 and His110. Also, it refers to methods for producing antibodies that comprise the cultivation of a host cell with a nucleic acid that encodes them, and the immunization of an animal against a polypeptide comprising the MG1-MG2 domain of the beta chain (SEQ ID NO : 40) from C5. Furthermore, it refers to an article of manufacture that contains a pharmaceutical formulation based on an anti-C5 antibody and a pharmaceutically acceptable buffer selected from bacteriostatic water for injection (BWFI) buffered with phosphate saline, Ringer's solution and dextrose solution, for its use as medicine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016120325 | 2016-06-17 | ||
| PCT/JP2017/022253 WO2017217524A1 (en) | 2016-06-17 | 2017-06-16 | Anti-c5 antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240825A1 true PE20240825A1 (en) | 2024-04-18 |
Family
ID=59969459
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002969A PE20240825A1 (en) | 2016-06-17 | 2017-06-16 | ANTI-C5 ANTIBODIES AND METHODS OF USE |
| PE2018003148A PE20190394A1 (en) | 2016-06-17 | 2017-06-16 | ANTI-C5 ANTIBODIES AND METHODS OF USE |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018003148A PE20190394A1 (en) | 2016-06-17 | 2017-06-16 | ANTI-C5 ANTIBODIES AND METHODS OF USE |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3472316A4 (en) |
| JP (3) | JP6202774B1 (en) |
| KR (2) | KR101852739B1 (en) |
| CN (3) | CN115960223A (en) |
| AU (1) | AU2017285763B2 (en) |
| BR (1) | BR112018075688A2 (en) |
| CA (1) | CA3021956A1 (en) |
| CL (1) | CL2018003573A1 (en) |
| CR (1) | CR20190013A (en) |
| EA (1) | EA201990018A1 (en) |
| IL (2) | IL300611A (en) |
| MX (2) | MX2018015030A (en) |
| MY (1) | MY187848A (en) |
| PE (2) | PE20240825A1 (en) |
| PH (1) | PH12018502354A1 (en) |
| SG (2) | SG11201705584VA (en) |
| TW (4) | TW202337903A (en) |
| UA (1) | UA126561C2 (en) |
| WO (1) | WO2017217524A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5624276B2 (en) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | Methods for controlling blood kinetics of antibodies |
| JP5334319B2 (en) | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Method for modifying isoelectric point of antibody by amino acid substitution of CDR |
| KR20220162801A (en) | 2008-04-11 | 2022-12-08 | 추가이 세이야쿠 가부시키가이샤 | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| KR102515796B1 (en) | 2014-12-19 | 2023-03-30 | 추가이 세이야쿠 가부시키가이샤 | Anti-c5 antibodies and methods of use |
| AU2017283470B2 (en) | 2016-06-14 | 2024-03-21 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibodies and uses thereof |
| MX2018015030A (en) * | 2016-06-17 | 2019-04-22 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use. |
| US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
| JP2020536097A (en) * | 2017-10-04 | 2020-12-10 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Dosage and administration of anti-C5 antibody for the treatment of patients with membranous proliferative glomerulonephritis |
| JP2021506241A (en) | 2017-12-13 | 2021-02-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Anti-C5 antibody combination and its use |
| MX2021002710A (en) * | 2018-09-06 | 2021-09-23 | Univ Pennsylvania | Humanized anti-c5 antibodies and uses thereof. |
| US20220204602A1 (en) * | 2019-04-24 | 2022-06-30 | The Trustees Of The University Of Pennsylvania | Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof |
| CN113563467A (en) * | 2020-04-28 | 2021-10-29 | 上海普铭生物科技有限公司 | Antibodies against human complement protein C5 and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0230985Y2 (en) | 1985-07-08 | 1990-08-21 | ||
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| WO2002102110A1 (en) | 2001-06-12 | 2002-12-19 | Telefonaktiebolaget Lm Ericsson (Publ) | Synchronisation in a umts terrestrial radio access network (utran) |
| US7432356B2 (en) | 2001-08-17 | 2008-10-07 | Genentech, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b |
| JP4333939B2 (en) | 2001-08-27 | 2009-09-16 | ロード・コーポレーション | Trolley wire suspension system |
| DE10253331A1 (en) | 2002-11-14 | 2004-06-03 | Symrise Gmbh & Co. Kg | Use of trans-pellitori as a flavoring |
| US7267849B2 (en) | 2004-03-02 | 2007-09-11 | Nitto Denko Corporation | Compensator for liquid crystal display |
| KR20080069889A (en) | 2007-03-20 | 2008-07-29 | (주)화도 | Pe pipe |
| US20100166748A1 (en) * | 2007-03-22 | 2010-07-01 | Novartis Ag | C5 Antigens and Uses Thereof |
| WO2008126921A1 (en) | 2007-04-11 | 2008-10-23 | Sekisui Chemical Co., Ltd. | Method for production of crosslinked polyvinyl acetal resin, and crosslinked polyvinyl acetal resin |
| KR20220162801A (en) * | 2008-04-11 | 2022-12-08 | 추가이 세이야쿠 가부시키가이샤 | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| JP5815403B2 (en) * | 2008-08-05 | 2015-11-17 | ノバルティス アーゲー | Compositions and methods relating to antibodies targeting complement protein C5 |
| KR20100054403A (en) | 2008-11-14 | 2010-05-25 | 삼성전자주식회사 | Online composition apparatus and method for writing by multiple participants |
| TW201206466A (en) * | 2010-03-11 | 2012-02-16 | Rinat Neuroscience Corp | Antibodies with pH dependent antigen binding |
| MX2012010481A (en) * | 2010-03-11 | 2012-10-09 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING. |
| KR20110111007A (en) | 2010-04-02 | 2011-10-10 | 이화여자대학교 산학협력단 | Octahydro-binaphthol derivatives for l/d optical conversion and optical resolution |
| KR20110122011A (en) | 2010-05-03 | 2011-11-09 | 황보철종 | System for administrating combine store point and method therefor |
| AU2013302925B2 (en) * | 2012-08-13 | 2018-07-05 | Regeneron Pharmaceuticals, Inc. | Anti-PCSK9 antibodies with pH-dependent binding characteristics |
| RU2018125515A (en) * | 2013-01-31 | 2018-10-29 | СЕУЛ НЭШНЛ ЮНИВЕРСИТИ Ар энд ДиБи ФАУНДЕЙШН | ANTIBODY AGAINST C5 AND METHOD FOR PREVENTING AND TREATING COMPLEMENTAL DISEASES |
| EP3473272A1 (en) * | 2013-03-29 | 2019-04-24 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| NZ711451A (en) * | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| KR102515796B1 (en) * | 2014-12-19 | 2023-03-30 | 추가이 세이야쿠 가부시키가이샤 | Anti-c5 antibodies and methods of use |
| PE20181402A1 (en) * | 2015-12-18 | 2018-09-07 | Chugai Pharmaceutical Co Ltd | ANTI-C5 ANTIBODIES AND METHODS OF USE |
| MX2018015030A (en) * | 2016-06-17 | 2019-04-22 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use. |
-
2017
- 2017-06-16 MX MX2018015030A patent/MX2018015030A/en unknown
- 2017-06-16 PE PE2023002969A patent/PE20240825A1/en unknown
- 2017-06-16 TW TW112120479A patent/TW202337903A/en unknown
- 2017-06-16 UA UAA201810992A patent/UA126561C2/en unknown
- 2017-06-16 CN CN202211018018.5A patent/CN115960223A/en active Pending
- 2017-06-16 WO PCT/JP2017/022253 patent/WO2017217524A1/en active Application Filing
- 2017-06-16 TW TW111107923A patent/TWI807666B/en active
- 2017-06-16 TW TW106120143A patent/TWI610941B/en active
- 2017-06-16 EP EP17813418.5A patent/EP3472316A4/en active Pending
- 2017-06-16 KR KR1020177020545A patent/KR101852739B1/en active IP Right Grant
- 2017-06-16 CN CN202211023851.9A patent/CN115925922A/en active Pending
- 2017-06-16 CR CR20190013A patent/CR20190013A/en unknown
- 2017-06-16 SG SG11201705584VA patent/SG11201705584VA/en unknown
- 2017-06-16 TW TW106141573A patent/TWI789369B/en active
- 2017-06-16 KR KR1020187010179A patent/KR102226975B1/en active IP Right Grant
- 2017-06-16 AU AU2017285763A patent/AU2017285763B2/en active Active
- 2017-06-16 EA EA201990018A patent/EA201990018A1/en unknown
- 2017-06-16 BR BR112018075688-1A patent/BR112018075688A2/en unknown
- 2017-06-16 PE PE2018003148A patent/PE20190394A1/en unknown
- 2017-06-16 CN CN201780036916.4A patent/CN109312326B/en active Active
- 2017-06-16 JP JP2017118226A patent/JP6202774B1/en active Active
- 2017-06-16 IL IL300611A patent/IL300611A/en unknown
- 2017-06-16 SG SG10201800265UA patent/SG10201800265UA/en unknown
- 2017-06-16 CA CA3021956A patent/CA3021956A1/en active Pending
- 2017-06-16 MY MYPI2018002581A patent/MY187848A/en unknown
- 2017-08-28 JP JP2017162934A patent/JP7032077B2/en active Active
-
2018
- 2018-11-08 PH PH12018502354A patent/PH12018502354A1/en unknown
- 2018-12-04 MX MX2023001360A patent/MX2023001360A/en unknown
- 2018-12-12 CL CL2018003573A patent/CL2018003573A1/en unknown
- 2018-12-12 IL IL263657A patent/IL263657A/en unknown
-
2022
- 2022-02-24 JP JP2022026406A patent/JP2022091748A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240825A1 (en) | ANTI-C5 ANTIBODIES AND METHODS OF USE | |
| CO2021006092A2 (en) | Il-15 / il-15ralpha-fc fusion proteins targeting pd-1 and uses thereof in combination therapies | |
| CO2017006651A2 (en) | Anti-c5 antibodies | |
| CO2018007374A2 (en) | Anti-c5 antibodies and methods of use | |
| CO2018012415A2 (en) | Specific binding proteins and uses thereof | |
| PE20150605A1 (en) | ACTIVABLE ANTIBODIES THAT JOIN THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR | |
| ES2676205T3 (en) | Stable antibody formulations for the human PD-1 receptor of programmed death and related treatments | |
| PE20181092A1 (en) | ANTI-PD1 ANTIBODIES AND METHODS OF USE | |
| AR092216A1 (en) | STABLE FORMULATIONS OF ANTIBODIES AGAINST TSLP | |
| BR112014020019A8 (en) | recombinant poxviral vectors expressing both rabies and ox40 proteins and vaccines made from these | |
| CL2012000269A1 (en) | A highly concentrated subcutaneous injectable pharmaceutical formulation of an anti-her2 antibody comprising said antibody, a buffer, a stabilizer, a non-ionic surfactant and a hyaluronidase enzyme; injection device; kit and use of the formulation to treat diseases such as cancer. | |
| PE20200757A1 (en) | AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND ITS USES | |
| PE20181054A1 (en) | HUMANIZED ANTI-CD19 ANTIBODIES AND METHODS OF USE | |
| EA201291133A1 (en) | ANTIBODIES, HAVING A REDUCED IMMUNOGENICITY IN THE HUMAN BODY | |
| UY30525A1 (en) | DIRECTED UNION AGENTS WHOSE WHITE IS THE PDGFR-ALFA AND ITS USES | |
| EA202092202A1 (en) | ROR ANTIBODY CONSTRUCTIONS | |
| PE20180741A1 (en) | ANTI-CD154 ANTIBODY WITH IMPROVED UNION CHARACTERISTICS, FUNCTIONALITY AND SAFETY AND USE IN HUMAN IMMUNOTHERAPY | |
| DOP2018000019A (en) | IMMUNOCONJUGADOS OF IL22 | |
| MX2020004063A (en) | Systems and methods to produce b cells genetically modified to express selected antibodies. | |
| AR077972A1 (en) | ANTIBODIES AGAINST CDCP1 INTENDED FOR CANCER TREATMENT | |
| UY35250A (en) | ANTI-LAMP1 ANTIBODIES AND CONJUGATES ANTIBODY DRUG, AND USES OF THESE. | |
| MX2015005045A (en) | Vaccine for preventing porcine edema disease. | |
| NZ704188A (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
| RU2020109137A (en) | VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS | |
| BR112017002206A2 (en) | koc1-derived peptide and vaccine including the same |